Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective

Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients... Bone Marrow Transplantation (2018) 53:1210–1213 https://doi.org/10.1038/s41409-018-0178-5 CORRESPONDENCE Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective 1 1 1 1 1 1 ● ● ● ● ● ● Talha Badar Parameswaran Hari Saurabh Chhabra Binod Dhakal William R. Drobyski Timothy S. Fenske 1 1 1 1 1 1 ● ● ● ● ● Mehdi Hamadani Marcelo Pasquini Wael Saber Nirav N. Shah Bronwen E. Shaw Anita D’Souza Received: 2 January 2018 / Revised: 7 March 2018 / Accepted: 23 March 2018 / Published online: 20 April 2018 © Macmillan Publishers Limited, part of Springer Nature 2018 To the Editor: Light-chain amyloidosis (AL) is a malignant We switched to PG-free melphalan for auto-HCT con- plasma cell disorder, characterized by misfolded fibrillar ditioning on 15 November 2016. Herein, we compare early protein deposition in vitals organs of the body, leading to post-transplant outcomes of AL patients in the year before organ failure and eventually death [1]. Treatment is directed and after the change. We retrospectively analyzed AL at eradicating the underlying plasma cell clone using sys- patients who underwent auto-HCT from 31 October 2015 to temic chemotherapy [2]. Autologous hematopoietic http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Bone Marrow Transplantation Springer Journals

Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective

Download PDF
4 pages

Loading next page...
 
/lp/springer-journals/use-of-propylene-glycol-free-melphalan-conditioning-in-light-chain-xsdDrC08i8

References (11)

Publisher
Springer Journals
Copyright
Copyright © 2018 by Macmillan Publishers Limited, part of Springer Nature
Subject
Medicine & Public Health; Medicine/Public Health, general; Internal Medicine; Cell Biology; Public Health; Hematology; Stem Cells
ISSN
0268-3369
eISSN
1476-5365
DOI
10.1038/s41409-018-0178-5
Publisher site
See Article on Publisher Site

Abstract

Bone Marrow Transplantation (2018) 53:1210–1213 https://doi.org/10.1038/s41409-018-0178-5 CORRESPONDENCE Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective 1 1 1 1 1 1 ● ● ● ● ● ● Talha Badar Parameswaran Hari Saurabh Chhabra Binod Dhakal William R. Drobyski Timothy S. Fenske 1 1 1 1 1 1 ● ● ● ● ● Mehdi Hamadani Marcelo Pasquini Wael Saber Nirav N. Shah Bronwen E. Shaw Anita D’Souza Received: 2 January 2018 / Revised: 7 March 2018 / Accepted: 23 March 2018 / Published online: 20 April 2018 © Macmillan Publishers Limited, part of Springer Nature 2018 To the Editor: Light-chain amyloidosis (AL) is a malignant We switched to PG-free melphalan for auto-HCT con- plasma cell disorder, characterized by misfolded fibrillar ditioning on 15 November 2016. Herein, we compare early protein deposition in vitals organs of the body, leading to post-transplant outcomes of AL patients in the year before organ failure and eventually death [1]. Treatment is directed and after the change. We retrospectively analyzed AL at eradicating the underlying plasma cell clone using sys- patients who underwent auto-HCT from 31 October 2015 to temic chemotherapy [2]. Autologous hematopoietic

Journal

Bone Marrow Transplantation – Springer Journals

Published: Apr 20, 2018

There are no references for this article.